New Drug Doubles Survival for Pancreatic Cancer | Science News

U.S. just approved a game-changing drug for pancreatic cancer—daraxonrasib, a two-pill-a-day treatment that’s doubling survival times for metastatic patients who’ve failed chemo. In trials, median survival jumped from 6.5 to over 13 months, with some living years—a rare win in a disease with a dismal five-year survival rate. This breakthrough offers new hope when all else fails, and while pricing is pending, the impact on lives is already undeniable. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/9bac7749060cbfa1